Samsara BioCapital’s Immunocore IMCR Stock Holding History

Samsara BioCapital’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-80,963	Closed	-$4.2M	–	43
2023 Q3	$4.2M	Hold	80,963	–	–	1.29%	22
2023 Q2	$4.85M	Hold	80,963	–	–	0.85%	21
2023 Q1	$4M	Hold	80,963	–	–	0.83%	23
2022 Q4	$4.62M	Hold	80,963	–	–	0.99%	22
2022 Q3	$3.8M	Sell	80,963 -80,000	-50%	-$3.81M	0.89%	25
2022 Q2	$6.01M	Hold	160,963	–	–	1.6%	17
2022 Q1	$4.81M	Buy	160,963 +96,963	+152%	+$2.45M	1.21%	20
2021 Q4	$2.19M	Hold	64,000	–	–	0.43%	35
2021 Q3	$2.37M	Hold	64,000	–	–	0.37%	37
2021 Q2	$2.5M	Sell	64,000 -16,000	-20%	-$618K	0.31%	39
2021 Q1	$3.41M	Buy	+80,000	New	+$3.56M	0.63%	34

Other funds holding IMCR

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Samsara BioCapital's IMCR Position: Q4 2023 in Review

Samsara BioCapital sold out of Immunocore (IMCR) in Q4 2023, closing a stake of 80,963 shares — an estimated $4.2M sold.

Samsara BioCapital first reported a position in IMCR in Q1 2021 and held it in 11 quarters. The position peaked at $6.01M in Q2 2022. 133 funds tracked by Wall St. Rank hold IMCR as of Q4 2023.

Samsara BioCapital reported no remaining Immunocore position as of Q4 2023 after selling out during the quarter.
Samsara BioCapital sold 80,963 Immunocore shares in Q4 2023, an estimated $4.2M.
Samsara BioCapital first reported a position in Immunocore in Q1 2021 and held it in 11 quarters.
Samsara BioCapital's Immunocore position peaked at $6.01M in Q2 2022.
133 funds tracked by Wall St. Rank held Immunocore as of Q4 2023.

Based on Samsara BioCapital's 13F filing for Q4 2023, filed 14 Feb 2024.